Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States

BACKGROUND: Dolutegravir(DTG)/lamivudine(3TC) is the first 2-drug regimen recommended as an initial treatment for people living with HIV (PLHIV). OBJECTIVE: To assess the cost-effectiveness and potential budget impact of DTG/3TC in the US healthcare setting. METHODS: A previously published hybrid de...

Descripción completa

Detalles Bibliográficos
Autores principales: Butler, Karin, Anderson, Sarah-Jane, Hayward, Olivia, Jacob, Ian, Punekar, Yogesh Suresh, Evitt, Lee Alexandra, Oglesby, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391195/
https://www.ncbi.nlm.nih.gov/pubmed/34185564
http://dx.doi.org/10.18553/jmcp.2021.27.7.891

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391195/
https://www.ncbi.nlm.nih.gov/pubmed/34185564
http://dx.doi.org/10.18553/jmcp.2021.27.7.891

Ejemplares similares